Literature DB >> 27306604

Pattern of tumour growth of the primary colon cancer predicts long-term outcome after resection of liver metastases.

Lidewij Spelt1, Agata Sasor2, Daniel Ansari1, Roland Andersson1.   

Abstract

OBJECTIVE: To identify significant predictive factors for overall survival (OS) and disease-free survival (DFS) after liver resection for colon cancer metastases, with special focus on features of the primary colon cancer, such as lymph node ratio (LNR), vascular invasion, and perineural invasion.
METHODS: Patients operated for colonic cancer liver metastases between 2006 and 2014 were included. Details on patient characteristics, the primary colon cancer operation and metastatic disease were collected. Multivariate analysis was performed to select predictive variables for OS and DFS.
RESULTS: Median OS and DFS were 67 and 20 months, respectively. 1-, 3- and 5-year OS were 97, 76, and 52%. 1-, 3- and 5-year DFS were 65, 42, and 37%. Multivariate analysis showed LNR to be an independent predictive factor for DFS but not for OS. Other identified predictive factors were vascular and perineural invasion of the primary colon cancer, size of the largest metastasis and severe complications after liver surgery for OS, and perineural invasion, number of liver metastases and preoperative CEA-level for DFS. Traditional N-stage was also considered to be an independent predictive factor for DFS in a separate multivariate analysis.
CONCLUSIONS: LNR and perineural invasion of the primary colon cancer can be used as a prognostic variable for DFS after a concomitant liver resection for colon cancer metastases. Vascular and perineural invasion of the primary colon cancer are predictive for OS.

Entities:  

Keywords:  Colonic neoplasms; disease-free survival; liver resection; lymph nodes; metastasis; survival analysis

Mesh:

Year:  2016        PMID: 27306604     DOI: 10.1080/00365521.2016.1190400

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  The Critical Role of Tumor Size in Predicting Prognosis for T1 Colon Cancer.

Authors:  Weixing Dai; Shaobo Mo; Wenqiang Xiang; Lingyu Han; Qingguo Li; Renjie Wang; Ye Xu; Guoxiang Cai
Journal:  Oncologist       Date:  2019-11-20

2.  Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.

Authors:  Frederic Carsten Schmeel; Birgit Simon; Julian Alexander Luetkens; Frank Träber; Carsten Meyer; Leonard Christopher Schmeel; Amir Sabet; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-19       Impact factor: 4.553

3.  Primary lymph node ratio and hepatic resection for colorectal metastases.

Authors:  Daniel Ansari; William Torén; Roland Andersson
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

4.  The Critical Role of Tumor Size in Predicting Prognosis for T1 Colon Cancer.

Authors:  Weixing Dai; Shaobo Mo; Wenqiang Xiang; Lingyu Han; Qingguo Li; Renjie Wang; Ye Xu; Guoxiang Cai
Journal:  Oncologist       Date:  2019-11-20

5.  miR-210 is a Serological Biomarker for Predicting Recurrence and Prognosis of Colon Carcinoma Patients with Liver Metastases After Radiofrequency Ablation Treatment.

Authors:  Yong Zhang; Yu-Mei Zhou; Zu-Jian Zhang; Xin Li
Journal:  Cancer Manag Res       Date:  2020-09-25       Impact factor: 3.989

Review 6.  Literature review of imaging, pathological diagnosis, and outcomes of metachronous lung and pancreatic metastasis of cecal cancer.

Authors:  Xiang Wu; Shuping Zhou; Xinhua Zhou; Xiao Xu; Luoluo Wang; Yi Ruan; Jun Lu; Haili Li; Hongfeng Xu; Xinyi Ma; Hong Li
Journal:  World J Surg Oncol       Date:  2022-10-17       Impact factor: 3.253

7.  Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer.

Authors:  P Scherman; I Syk; E Holmberg; P Naredi; M Rizell
Journal:  BJS Open       Date:  2019-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.